Mangalam Drugs And Organics enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


46.1	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.7	0.7	2.6	0.9	2.7
105	105	81.2	87.9	68.3
151	—	—	—	—
105	105	78.6	87.0	65.7
₹95.31	—	—	—	—

209	209	230	224	—
50.6%	50.6%	35.3%	39.3%	—
0.70×	—	—	—	—

0.65×	—	—	—	—
−16.79×	—	—	—	—
−5.62×	—	—	—	—
232	232	318	369	—
−9.0	−14.9	35.8	17.4	—
−26.8	−33.1	19.2	2.7	—
—	4.2	42.6	−11.1	39.5
−7.7	−7.7	22.4	−11.1	11.6
—	−9.1	22.4	−13.6	8.4
—	11.9	20.2	0.0	27.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANGALAM₹29.11

Mangalam Drugs And Organics Limited

· Pharma & Health

₹ CrorePeersBIOFILCHEM LASA VINEETLAB ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹46.1 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	46.1
- Cash, Equiv & ST Investments	2.7	0.9	2.6	0.7	0.7
+ Total Debt	68.3	87.9	81.2	105.5	105.5
Enterprise Value	—	—	—	—	150.9
Net Debt (memo)	65.7	87.0	78.6	104.8	104.8
EV per Share	—	—	—	—	95.31

Total Capital	—	223.7	230.1	208.5	208.5
Total Debt/Total Capital	—	39.31	35.27	50.58	50.58
Total Debt/EV	—	—	—	—	0.70

EV/Sales	—	—	—	—	0.65
EV/EBITDA	—	—	—	—	-16.79
EV/EBIT	—	—	—	—	-5.62
Reference Items — Trailing FY Values
Sales	—	368.6	318.2	232.1	232.4
EBITDA	—	17.4	35.8	-14.9	-9.0
EBIT	—	2.7	19.2	-33.1	-26.8
Operating Cash Flow	39.5	-11.1	42.6	4.2	—
Free Cash Flow	11.6	-11.1	22.4	-7.7	-7.7
FCFF (free cash flow to the firm)	8.4	-13.6	22.4	-9.1	—
Capital Expenditure	27.9	0.0	20.2	11.9	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.